Possible modulation of the antidiabetic effect of rosiglitazone by buspirone

Abstract

Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from relative or absolute insulin deficiency with or without insulin resistance. As anxiolytics may have influence on glycemic control in diabetics, the present study was conducted to investigate the possible influence of buspirone in streptozotocin-induced DM and its possible interactions with rosiglitazone, an insulin sensitizer. Diabetes was induced by streptozotocin (50mg/kg i.p.). Rats were classified into five groups namely: normal control, diabetic control, rosiglitazone (10mg/kg p.o.), buspirone (20mg/kg i.p.) or combination of both rosiglitazone and buspirone, respectively. All groups received daily treatments for 2weeks after induction of DM including the normal group which received 1% Tween 80. There was no significant interaction between rosiglitazone and buspirone on the levels of serum glucose, insulin and C-peptide or liver glycogen content. Similarly, no interaction was observed between rosiglitazone and buspirone on oxidative stress parameters including serum malondialdehyde and blood glutathione levels or blood superoxide dismutase activity. In conclusion, the present study revealed that co-administration of buspirone with rosiglitazone does not produce serious reactions and buspirone can be safely administered as an anxiolytic in diabetic patients treated with rosiglitazone.